IL33 and autoimmune disease: The ability of apigenin and luteolin to regulate LPS-induced microglia activation and subsequent pro-inflammatory IL-31 and IL-33 mediators may be useful in the treatment of inflammatory diseases in the CNS including Alzheimer’s disease, malaria infections, itch caused by the release of itch mediator within the CNS, and autoimmune diseases like multiple sclerosis, where there is a positive correlation with IL-31 or IL-33 [6,25,26,27].